What are the obligations of pharmaceutical companies in a global health emergency?

TY - JOUR

T1 - What are the obligations of pharmaceutical companies in a global health emergency?

AU - Emanuel, Ezekiel J.

AU - Buchanan, Allen

AU - Chan, Shuk Ying

AU - Fabre, Cécile

AU - Halliday, Daniel

AU - Heath, Joseph

AU - Herzog, Lisa

AU - Leland, R. J.

AU - McCoy, Matthew S.

AU - Norheim, Ole F.

AU - Saenz, Carla

AU - Schaefer, G. Owen

AU - Tan, Kok Chor

AU - Wellman, Christopher Heath

AU - Wolff, Jonathan

AU - Persad, Govind

N1 - Funding Information: EJE reports serving as a partner at Oak HC/FT, Embedded Healthcare, and COVID-19 Recovery Consulting; receiving personal fees and non-financial support from Genentech Oncology, Council of Insurance Agents and Brokers, America's Health Insurance Plans, Montefiore Physician Leadership Academy, Medical Home Network, Healthcare Financial Management Association, Ecumenical Center–UT Health, Associação Nacional de Hospitais Privados, National Alliance of Healthcare Purchaser Coalitions, Optum Labs, Massachusetts Association of Health Plans, District of Columbia Hospital Association, Washington University, Optum, Brown University, McKay Lab, American Society for Surgery of the Hand, Association of American Medical Colleges, America's Essential Hospitals, Johns Hopkins University, National Resident Matching Program, Shore Memorial Health System, Tulane University, Oregon Health and Science University, United Health Group, Blue Cross Blue Shield, and Informa Connect; receiving non-financial support from the Center for Global Development, The Atlantic, Goldman Sachs, and RAND; and was a board member for Village MD and Oncology Analytics, outside the submitted work. GP reports grants from Greenwall Foundation and personal fees from the American Society of Clinical Oncology Post and WHO, outside the submitted work. LH received an honorarium as part of the general funding of the project. All other authors declare no competing interests. Funding Information: We thank Amaya Diana, Aaron Glickman, and Patricia Hong for their assistance with research, critical review of the manuscript, and other details. We also thank Florencia Luna for useful conversations. The Colton Family Foundation partly supported the research for this project. The views expressed here, and any errors, are solely those of the authors and should not be attributed to any of their employers. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

PY - 2021/9/11

Y1 - 2021/9/11

UR - http://www.scopus.com/inward/record.url?scp=85114693623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85114693623&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(21)01378-7

DO - 10.1016/S0140-6736(21)01378-7

M3 - Review article

C2 - 34364412

AN - SCOPUS:85114693623

SN - 0140-6736

VL - 398

SP - 1015

EP - 1020

JO - The Lancet

JF - The Lancet

IS - 10304

ER -